Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis
Key claim: Gecacitinib hydrochloride, a novel JAK/ACVR1 inhibitor, is being evaluated for its efficacy and safety in preventing acute graft-versus-host disease when combined with ATG in myelofibrosis patients undergoing allogeneic hematopoietic stem cell transplantation.
Abstract
Gecacitinib hydrochloride is a novel JAK/ACVR1 inhibitor approved for intermediate- and high-risk myelofibrosis (MF). Clinical and real-world data demonstrate significant efficacy in spleen reduction, symptom relief, and anemia improvement, with favorable safety and tolerability. Preclinical studies confirm that this agent can mitigate GVHD and suppress inflammation. MF patients undergoing allo-HSCT are at risk of delayed engraftment and aGVHD. Based on the immunomodulatory effects of JAK inhibitors, gecacitinib is expected to have potential for aGVHD prophylaxis. This study aims to evaluate the efficacy and safety of geltrectinib hydrochloride combined with ATG for preventing aGVHD in MF patients after allo-HSCT.
Why this matters
GVHD prophylaxis remains a major determinant of allo-HSCT success in myelofibrosis, and JAK inhibition (via ruxolitinib) has emerged as a promising peri-transplant strategy. Gecacitinib’s dual JAK/ACVR1 mechanism could expand the therapeutic toolkit by simultaneously targeting GVHD-driving cytokine signaling and MF-specific ACVR1 biology, potentially offering advantages over single-pathway JAK inhibition. Early trial data will inform whether this becomes a viable alternative or adjunct in the evolving peri-transplant prophylaxis landscape.